Neural Therapeutics Inc. focuses on developing ethnobotanical dietary supplements and psychedelic-based drugs for mental health treatment. While the company has a solid liquidity position with a current ratio of 1.84, its return on assets is concerningly low at -311.4%, indicating inefficiency in asset utilization. Additionally, the significant drop in stock price by 33.33% suggests market volatility and potential investor skepticism. Overall, while there are strengths in liquidity, the negative ROA and market performance raise concerns about the company's financial health and operational effectiveness.
Loading financial metrics...
Company is burning $76K per quarter with $251K in cash. Approximately 3.3 quarters of runway at current burn rate.
Company posted a loss of $-1.4M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $306K over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (April 30, 2025)